194 related articles for article (PubMed ID: 27699276)
1. PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Thura M; Al-Aidaroos AQO; Yong WP; Kono K; Gupta A; Lin YB; Mimura K; Thiery JP; Goh BC; Tan P; Soo R; Hong CW; Wang L; Lin SJ; Chen E; Rha SY; Chung HC; Li J; Nandi S; Yuen HF; Zhang SD; Guan YK; So J; Zeng Q
JCI Insight; 2016 Jun; 1(9):e87607. PubMed ID: 27699276
[TBL] [Abstract][Full Text] [Related]
2. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2019 Jun; 10(1):2484. PubMed ID: 31171773
[TBL] [Abstract][Full Text] [Related]
3. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; Yang S; Thura M; Al-Aidaroos AQ; Chng WJ; Zeng Q; Goh BC
Target Oncol; 2023 May; 18(3):391-402. PubMed ID: 37060431
[TBL] [Abstract][Full Text] [Related]
4. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Jul; 4(1):923. PubMed ID: 34326464
[TBL] [Abstract][Full Text] [Related]
5. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP; Thura M; Gupta A; Tan SH; Kuan KKY; Ang KH; Merchant K; Chang KTE; Yon HY; Chen Y; Cheng MHW; Mahadev A; Ng MCH; Seng MS; Iyer P; Chia PL; Soh SY; Zeng Q
Mol Ther Oncolytics; 2023 Sep; 30():153-166. PubMed ID: 37674627
[TBL] [Abstract][Full Text] [Related]
6. RNAi‑mediated knockdown of PRL‑3 inhibits cell invasion and downregulates ERK 1/2 expression in the human gastric cancer cell line, SGC‑7901.
Cao Y; Tu Y; Mei J; Li Z; Jie Z; Xu S; Xu L; Wang S; Xiong Y
Mol Med Rep; 2013 Jun; 7(6):1805-11. PubMed ID: 23589069
[TBL] [Abstract][Full Text] [Related]
7. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.
Chia PL; Ang KH; Thura M; Zeng Q
Theranostics; 2023; 13(6):1876-1891. PubMed ID: 37064866
[TBL] [Abstract][Full Text] [Related]
8. [Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer].
Cai SR; Wang Z; Chen CQ; Cui J; Zhang CH; He YL; Zhan WH
Zhonghua Wai Ke Za Zhi; 2008 Apr; 46(8):618-21. PubMed ID: 18844061
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling.
Csoboz B; Gombos I; Tatrai E; Tovari J; Kiss AL; Horvath I; Vigh L
Cell Commun Signal; 2018 Aug; 16(1):51. PubMed ID: 30157875
[TBL] [Abstract][Full Text] [Related]
10. [Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation].
Cai SR; Chen CQ; Wang Z; He YL; Cui J; Wu WH; Wu H; Zhan WH
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(33):2326-30. PubMed ID: 19087692
[TBL] [Abstract][Full Text] [Related]
11. Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Lv J; Liu C; Huang H; Meng L; Jiang B; Cao Y; Zhou Z; She T; Qu L; Wei Song S; Shou C
Gene Ther; 2013 Aug; 20(8):834-45. PubMed ID: 23364316
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Guo K; Tang JP; Tan CP; Wang H; Zeng Q
Cancer Biol Ther; 2008 May; 7(5):750-7. PubMed ID: 18364570
[TBL] [Abstract][Full Text] [Related]
13. Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Matsukawa Y; Semba S; Kato H; Koma Y; Yanagihara K; Yokozaki H
Pathobiology; 2010; 77(3):155-62. PubMed ID: 20516731
[TBL] [Abstract][Full Text] [Related]
14. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Wang Z; Cai SR; He YL; Zhan WH; Chen CQ; Cui J; Wu WH; Wu H; Song W; Zhang CH; Peng JJ; Huang XH
Ann Surg Oncol; 2009 Jan; 16(1):208-19. PubMed ID: 19009246
[TBL] [Abstract][Full Text] [Related]
15. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Li J; Guo K; Koh VW; Tang JP; Gan BQ; Shi H; Li HX; Zeng Q
Clin Cancer Res; 2005 Mar; 11(6):2195-204. PubMed ID: 15788667
[TBL] [Abstract][Full Text] [Related]
16. Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Guzińska-Ustymowicz K; Kiśluk J; Terlikowski SJ; Pryczynicz A; Niewiarowska K; Ustymowicz M; Hawryluk M; Południewski M; Kemona A
Adv Med Sci; 2013; 58(2):221-6. PubMed ID: 23729584
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.
Sun W; Zhang Y; Wong KC; Liu K; Yang Y; Wu B; Tong JHM; Chan AWH; Chan HLY; Yu J
Hepatology; 2018 Jun; 67(6):2302-2319. PubMed ID: 29266303
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
Peng L; Li Y; Meng L; Shou C
Hybrid Hybridomics; 2004 Feb; 23(1):23-7. PubMed ID: 15000845
[TBL] [Abstract][Full Text] [Related]
19. PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.
Xiong J; Li Z; Zhang Y; Li D; Zhang G; Luo X; Jie Z; Liu Y; Cao Y; Le Z; Tan S; Zou W; Gong P; Qiu L; Li Y; Wang H; Chen H
Oncol Rep; 2016 Oct; 36(4):1819-28. PubMed ID: 27572739
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
Li Z; Zhang G; Li D; Jie Z; Chen H; Xiong J; Liu Y; Cao Y; Jiang M; Le Z; Tan S
Biochem Biophys Res Commun; 2015 Jan; 456(1):344-50. PubMed ID: 25475733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
